ABSTRACT
Treatment of diabetes mellitus includes lifestyle intervention, control of cardiovascular risk factors, and the use of pharmacotherapy to attain a glycemic target. A patient-centered approach is needed to choose the most appropriate antidiabetic drug considering the patients’ characteristics and comorbidities. Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter type-2 inhibitors are antidiabetic drugs that induce weight loss and have proven to be cardioprotective in patients with established cardiovascular disease or who are at high risk for cardiovascular disease. Moreover, sodium-glucose cotransporter type-2 inhibitors are beneficial in patients with type 2 diabetes who have a history of heart failure. Therefore, assessment of cardiovascular disease status and cardiovascular risk factors is essential in guiding the selection of glucose-lowering therapy.
